Ovalbumin-induced asthma leads to bone loss with Piezo channel suppression in mice

Weiqi Gao1, Takeshi Sawada1, Ailin Cao1

  • 1Division of Histology and Neuroanatomy, Department of Anatomy and Physiology, Faculty of Medicine, Saga University, Saga, Japan.

Communications Biology
|August 29, 2025
PubMed

Insights

Allergic asthma may lead to bone loss (osteopenia) by reducing osteoblast activity. Modulating Piezo channels could offer a therapeutic strategy against this bone loss.

Area of Science:

  • Bone Metabolism and Endocrinology
  • Allergic Inflammation and Immunology
  • Mechanobiology and Ion Channels

Background:

  • The relationship between allergic diseases and bone loss is not fully understood, often attributed to corticosteroid treatments.
  • Allergic inflammation's direct impact on bone metabolism requires further investigation.

Purpose of the Study:

  • To investigate the effects of allergic diseases, specifically asthma, on bone metabolism.
  • To explore the role of Piezo1 and Piezo2 channels in asthma-induced bone loss.

Main Methods:

  • Ovalbumin (OVA)-induced asthma model in mice.
  • Analysis of bone mass, osteoblast numbers, and Piezo channel expression in long bones.
  • Pharmacological modulation using a Piezo1 agonist and genetic deletion of Piezo2.

Main Results:

  • OVA-induced asthmatic mice exhibited lower bone mass and reduced mature osteoblasts compared to controls.
  • Expression of Piezo1 and Piezo2 channels was suppressed in asthmatic mice.
  • Piezo1 activation reversed OVA-induced bone loss, enhancing osteogenesis and collagen type I expression; Piezo2 deficiency exacerbated bone loss in asthmatic mice.

Conclusions:

  • Allergic asthma can induce osteopenia, independent of corticosteroid use.
  • Piezo channels (Piezo1 and Piezo2) are implicated in the bone loss associated with allergic asthma.
  • Piezo channel modulation presents a potential therapeutic target for preventing bone loss in allergic asthma.

Related Concept Videos